Clinical trial · Interventional
Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative
STANDARDIZEd Documentation and Assessments for Polycythemia Vera (STANDARDIZE-PV): A Quality Improvement Initiative
NCT07734272CI-TRIAL-00119787STANDARDIZE-PVnot yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this quality improvement initiative is to explore whether an electronic medical records-based templated progress note for polycythemia vera (PV) in addition to a standard-of-care pharmacist-collaborative ropeginterferon alfa-2b titration service is feasible, acceptable, and appropriate for clinicians who manage PV.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycythemia Vera | Polycythemia Vera | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Standardized progress note | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Standardized note with standard-of-care pharmacist support
- description
- Standardized progress note templates with opt-in option for standard-of-care pharmacist support of ropeginterferon alfa-2b titration
- interventionNames
- Behavioral: Standardized progress note
Primary outcomes (1)
- measure
- Feasibility of intervention
- timeFrame
- 12 months
- description
- Number of participants that are eligible who enroll in this initiative and rating of feasibility by a single question on a 5-point Likert scale with score \>3 indicating higher feasibility
Secondary outcomes (2)
- measure
- Acceptibility of intervention
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: \- Hematologists and medical oncologists within the Mass General Brigham network sites who treat at least one patient with PV in their outpatient clinic. Exclusion Criteria: * Clinicians who do not have an outpatient hematology or medical oncology clinic within Mass General Brigham. * Clinicians who do not utilize the EPIC electronic medical record (EMR) System as their method of patient progress note documentation.
References
Publications (0)
Data not yet available
No reference posted for this study.